FDA.reportPublic FDA data

tisotumab vedotin-tftv 40 MG Injection

RxCUI
2571099
RxNorm name
tisotumab vedotin-tftv 40 MG Injection
Display name
tisotumab vedotin-tftv 40 MG Injection
Full name
tisotumab vedotin-tftv 40 MG Injection
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:21

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761208Tivdaktisotumab vedotin-tftv351(a)Rx2026-10-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
c9fe3f32-4219-466e-acb9-3f609b4f4df1tisotumab vedotin-tftv 40 MG Injection [PSN] · tisotumab vedotin-tftv 40 MG Injection [SCD]210These highlights do not include all the information needed to use TIVDAK safely and effectively. See full prescribing information for TIVDAK. TIVDAK ® (tisotumab vedotin-tftv) for injection, for intravenous use Initial U.S. Approval: 202120251120